|
1
|
Beiki O, Hall P, Ekbom A and Moradi T:
Breast cancer incidence and case fatality among 4.7 million women
in relation to social and ethnic background: A population-based
cohort study. Breast Cancer Res. 14:R52012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lim E, Metzger-Filho O and Winer EP: The
natural history of hormone receptor-positive breast cancer.
Oncology (Williston Park). 26:pp. 688–694. pp. 6962012
|
|
3
|
Regan MM, Neven P, Giobbie-Hurder A,
Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I,
Wardley A, et al: BIG 1-98 Collaborative Group; International
Breast Cancer Study Group (IBCSG): Assessment of letrozole and
tamoxifen alone and in sequence for postmenopausal women with
steroid hormone receptor-positive breast cancer: The BIG 1-98
randomised clinical trial at 8·1 years median follow-up. Lancet
Oncol. 12:1101–1108. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Colditz GA: Relationship between estrogen
levels, use of hormone replacement therapy, and breast cancer. J
Natl Cancer Inst. 90:814–823. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lumachi F, Brunello A, Maruzzo M, Basso U
and Basso SM: Treatment of estrogen receptor-positive breast
cancer. Curr Med Chem. 20:596–604. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Higgins MJ and Stearns V: CYP2D6
polymorphisms and tamoxifen metabolism: Clinical relevance. Curr
Oncol Rep. 12:7–15. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Raha P, Thomas S and Munster PN:
Epigenetic modulation: A novel therapeutic target for overcoming
hormonal therapy resistance. Epigenomics. 3:451–470. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hurvitz SA and Pietras RJ: Rational
management of endocrine resistance in breast cancer: A
comprehensive review of estrogen receptor biology, treatment
options, and future directions. Cancer. 113:2385–2397. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Anzick SL, Kononen J, Walker RL, Azorsa
DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM and
Meltzer PS: AIB1, a steroid receptor coactivator amplified in
breast and ovarian cancer. Science. 277:965–968. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ravdin PM, Fritz NF, Tormey DC and Jordan
VC: Endocrine status of premenopausal node-positive breast cancer
patients following adjuvant chemotherapy and long-term tamoxifen.
Cancer Res. 48:1026–1029. 1988.PubMed/NCBI
|
|
11
|
Paridaens R, Sylvester RJ, Ferrazzi E,
Legros N, Leclercq G and Heuson JC: Clinical significance of the
quantitative assessment of estrogen receptors in advanced breast
cancer. Cancer. 46(Suppl): 2889–2895. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Di Gesualdo F, Capaccioli S and Lulli M: A
pathophysiological view of the long non-coding RNA world.
Oncotarget. 5:10976–10996. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Z, Shen J, Chan MT and Wu WK: TUG1: A
pivotal oncogenic long non-coding RNA of human cancers. Cell
Prolif. 49:471–475. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han P and Chang CP: Long non-coding RNA
and chromatin remodeling. RNA Biol. 12:1094–1098. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kornienko AE, Guenzl PM, Barlow DP and
Pauler FM: Gene regulation by the act of long non-coding RNA
transcription. BMC Biol. 11:592013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang HY, Liang F, Zhang JW, Wang F, Wang
L and Kang XG: Effects of long noncoding RNA-ROR on tamoxifen
resistance of breast cancer cells by regulating microRNA-205.
Cancer Chemother Pharmacol. 79:327–337. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li X, Wu Y, Liu A and Tang X: Long
non-coding RNA UCA1 enhances tamoxifena resistance in breast cancer
cells through a miR-18a-HIF1α feedback regulatory loop. Tumor Biol.
37:14733–14743. 2016. View Article : Google Scholar
|
|
18
|
Cai Y, He J and Zhang D: Suppression of
long non-coding RNA CCAT2 improves tamoxifen-resistant breast
cancer cells' response to tamoxifen. Mol Biol. 50:821–827. 2016.In
Russian.
|
|
19
|
Chen G, Wang Z, Wang D, Qiu C, Liu M, Chen
X, Zhang Q, Yan G and Cui Q: lncRNADisease: A database for
long-non-coding RNA-associated diseases. Nucleic Acids Res.
41D:D983–D986. 2013.
|
|
20
|
Lottin S, Adriaenssens E, Dupressoir T,
Berteaux N, Montpellier C, Coll J, Dugimont T and Curgy JJ:
Overexpression of an ectopic H19 gene enhances the tumorigenic
properties of breast cancer cells. Carcinogenesis. 23:1885–1895.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gupta RA, Shah N, Wang KC, Kim J, Horlings
HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xue M, Chen W and Li X: Urothelial cancer
associated 1: A long noncoding RNA with a crucial role in cancer. J
Cancer Res Clin Oncol. 142:1407–1419. 2016. View Article : Google Scholar
|
|
23
|
Huang J, Zhou N, Watabe K, Lu Z, Wu F, Xu
M and Mo YY: Long non-coding RNA UCA1 promotes breast tumor growth
by suppression of p27 (Kip1). Cell Death Dis. 5:e10082014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang XS, Zhang Z, Wang HC, Cai JL, Xu QW,
Li MQ, Chen YC, Qian XP, Lu TJ, Yu LZ, et al: Rapid identification
of UCA1 as a very sensitive and specific unique marker for human
bladder carcinoma. Clin Cancer Res. 12:4851–4858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tuo YL, Li XM and Luo J: Long noncoding
RNA UCA1 modulates breast cancer cell growth and apoptosis through
decreasing tumor suppressive miR-143. Eur Rev Med Pharmacol Sci.
19:3403–3411. 2015.PubMed/NCBI
|
|
26
|
Bian Z, Jin L, Zhang J, Yin Y, Quan C, Hu
Y, Feng Y, Liu H, Fei B, Mao Y, et al: lncRNA-UCA1 enhances cell
proliferation and 5-fluorouracil resistance in colorectal cancer by
inhibiting miR-204-5p. Sci Rep. 6:238922016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li GY, Wang W, Sun JY, Xin B, Zhang X,
Wang T, Zhang QF, Yao LB, Han H, Fan DM, et al: Long non-coding
RNAs AC026904.1 and UCA1: A 'one-two punch' for TGF-β-induced SNAI2
activation and epithelial-mesenchymal transition in breast cancer.
Theranostics. 8:2846–2861. 2018. View Article : Google Scholar :
|
|
28
|
Ringrose L and Paro R: Epigenetic
regulation of cellular memory by the Polycomb and Trithorax group
proteins. Annu Rev Genet. 38:413–443. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Haupt Y, Alexander WS, Barri G, Klinken SP
and Adams JM: Novel zinc finger gene implicated as myc collaborator
by retro-virally accelerated lymphomagenesis in E mu-myc transgenic
mice. Cell. 65:753–763. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sauvageau M and Sauvageau G: Polycomb
group proteins: Multi-faceted regulators of somatic stem cells and
cancer. Cell Stem Cell. 7:299–313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yap DB, Chu J, Berg T, Schapira M, Cheng
SW, Moradian A, Morin RD, Mungall AJ, Meissner B, Boyle M, et al:
Somatic mutations at EZH2 Y641 act dominantly through a mechanism
of selectively altered PRC2 catalytic activity, to increase H3K27
trimethylation. Blood. 117:2451–2459. 2011. View Article : Google Scholar :
|
|
32
|
Hu JJ, Song W, Zhang SD, Shen XH, Qiu XM,
Wu HZ, Gong PH, Lu S, Zhao ZJ, He ML, et al: HBx-upregulated lncRNA
UCA1 promotes cell growth and tumorigenesis by recruiting EZH2 and
repressing p27Kip1/CDK2 signaling. Sci Rep. 6:235212016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang C, Li X, Wang Y, Zhao L and Chen W:
Long non-coding RNA UCA1 regulated cell cycle distribution via CREB
through PI3-K dependent pathway in bladder carcinoma cells. Gene.
496:8–16. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xie X, Pan J, Wei L, Wu S, Hou H, Li X and
Chen W: Gene expression profiling of microRNAs associated with UCA1
in bladder cancer cells. Int J Oncol. 48:1617–1627. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen S, Shao C, Xu M, Ji J, Xie Y, Lei Y
and Wang X: Macrophage infiltration promotes invasiveness of breast
cancer cells via activating long non-coding RNA UCA1. Int J Clin
Exp Pathol. 8:9052–9061. 2015.PubMed/NCBI
|
|
36
|
You D, Jung SP, Jeong Y, Bae SY, Lee JE
and Kim S: Fibronectin expression is upregulated by PI-3K/Akt
activation in tamoxifen-resistant breast cancer cells. BMB Rep.
50:615–620. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xue M, Li X, Li Z and Chen W: Urothelial
carcinoma associated 1 is a hypoxia-inducible factor-1α-targeted
long noncoding RNA that enhances hypoxic bladder cancer cell
proliferation, migration, and invasion. Tumour Biol. 35:6901–6912.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Motawi TK, Abdelazim SA, Darwish HA, Elbaz
EM and Shouman SA: Modulation of tamoxifen cytotoxicity by caffeic
acid phenethyl ester in MCF-7 breast cancer cells. Oxid Med Cell
Longev. 2016:30171082016. View Article : Google Scholar
|
|
39
|
Grigsby JG, Parvathaneni K, Almanza MA,
Botello AM, Mondragon AA, Allen DM and Tsin AT: Effects of
tamoxifen versus raloxifene on retinal capillary endothelial cell
proliferation. J Ocul Pharmacol Ther. 27:225–233. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lu Y, Liu WG, Lu JH, Liu ZJ, Li HB, Liu
GJ, She HY, Li GY and Shi XH: lncRNA UCA1 promotes renal cell
carcinoma proliferation through epigenetically repressing p21
expression and negatively regulating miR-495. Tumour Biol.
39:10104283177016322017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen WM, Huang MD, Sun DP, Kong R, Xu TP,
Xia R, Zhang EB and Shu YQ: Long intergenic non-coding RNA 00152
promotes tumor cell cycle progression by binding to EZH2 and
repressing p15 and p21 in gastric cancer. Oncotarget. 7:9773–9787.
2016.PubMed/NCBI
|
|
42
|
Giordano A and Avantaggiati ML: p300 and
CBP: Partners for life and death. J Cell Physiol. 181:218–230.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Du J, Tong A, Wang F, Cui Y, Li C, Zhang Y
and Yan Z: The Roles of PI3K/AKT/mTOR and MAPK/ERK Signaling
Pathways in Human Pheochromocytomas. Int J Endocrinol.
2016:52869722016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liang MH, Wendland JR and Chuang DM:
Lithium inhibits Smad3/4 transactivation via increased CREB
activity induced by enhanced PKA and AKT signaling. Mol Cell
Neurosci. 37:440–453. 2008. View Article : Google Scholar
|
|
45
|
Plantamura I, Cosentino G and Cataldo A:
MicroRNAs and DNA-damaging drugs in breast cancer: Strength in
numbers. Front Oncol. 8:3522018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rocca A, Maltoni R, Bravaccini S, Donati C
and Andreis D: Clinical utility of fulvestrant in the treatment of
breast cancer: A report on the emerging clinical evidence. Cancer
Manag Res. 10:3083–3099. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xia H and Hui KM: Mechanism of cancer drug
resistance and the involvement of noncoding RNAs. Curr Med Chem.
21:3029–3041. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cheng N, Cai W, Ren S, Li X, Wang Q, Pan
H, Zhao M, Li J, Zhang Y, Zhao C, et al: Long non-coding RNA UCA1
induces non-T790M acquired resistance to EGFR-TKIs by activating
the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.
Oncotarget. 6:23582–23593. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pan J, Li X, Wu W, Xue M, Hou H, Zhai W
and Chen W: Long non-coding RNA UCA1 promotes cisplatin/gemcitabine
resistance through CREB modulating miR-196a-5p in bladder cancer
cells. Cancer Lett. 382:64–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu H, Wang G, Yang L, Qu J, Yang Z and
Zhou X: Knockdown of long non-coding RNA UCA1 Increases the
Tamoxifen Sensitivity of Breast cancer cells through inhibition of
Wnt/β-catenin pathway. PLoS One. 11:e01684062016. View Article : Google Scholar
|
|
51
|
Adams JM and Cory S: The Bcl-2 protein
family: Arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Deng J, Deng H, Liu C, Liang Y and Wang S:
Long non-coding RNA OIP5-AS1 functions as an oncogene in lung
adenocar-cinoma through targeting miR-448/Bcl-2. Biomed
Pharmacother. 98:102–110. 2018. View Article : Google Scholar
|
|
53
|
Taylor MA, Sossey-Alaoui K, Thompson CL,
Danielpour D and Schiemann WP: TGF-β upregulates miR-181a
expression to promote breast cancer metastasis. J Clin Invest.
123:150–163. 2013. View Article : Google Scholar
|
|
54
|
Srivastava N, Manvati S, Srivastava A, Pal
R, Kalaiarasan P, Chattopadhyay S, Gochhait S, Dua R and Bamezai
RN: miR-24-2 controls H2AFX expression regardless of gene copy
number alteration and induces apoptosis by targeting antiapoptotic
gene BCL-2: A potential for therapeutic intervention. Breast Cancer
Res. 13:R392011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Vanhaesebroeck B, Leevers SJ, Ahmadi K,
Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ and
Waterfield MD: Synthesis and function of 3-phosphorylated inositol
lipids. Annu Rev Biochem. 70:535–602. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yu X, Li R, Shi W, Jiang T, Wang Y, Li C
and Qu X: Silencing of microRNA-21 confers the sensitivity to
tamoxifen and fulvestrant by enhancing autophagic cell death
through inhibition of the PI3K-AKT-mTOR pathway in breast cancer
cells. Biomed Pharmacother. 77:37–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
de Groot RP, Ballou LM and Sassone-Corsi
P: Positive regulation of the cAMP-responsive activator CREM by the
p70 S6 kinase: An alternative route to mitogen-induced gene
expression. Cell. 79:81–91. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Linnerth NM, Greenaway JB, Petrik JJ and
Moorehead RA: cAMP response element-binding protein is expressed at
high levels in human ovarian adenocarcinoma and regulates ovarian
tumor cell proliferation. Int J Gynecol Cancer. 18:1248–1257. 2008.
View Article : Google Scholar : PubMed/NCBI
|
